Latest Financials News

Platinum Asset Management reported a sharp 86% drop in profit for FY25, driven by a 39% decline in funds under management amid sustained outflows and investment challenges. The company announced a transformative merger with L1 Capital, aiming to create a $16.5 billion asset manager.

GenusPlus Group Ltd has delivered record FY2025 financial results, driven by strong contract wins and strategic acquisitions, positioning itself as a key player in Australia’s energy transition. The company forecasts robust earnings growth for FY2026 backed by a $2 billion orderbook.

GenusPlus Group has delivered a standout FY2025 with record revenue and profits, underpinned by strategic acquisitions and a booming renewable energy pipeline.

GenusPlus Group Ltd has reported a robust 36% increase in revenue and an 84% surge in net profit for FY2025, driven by strategic acquisitions and growth in the renewable energy sector. The company also declared a higher fully franked dividend, reflecting confidence in its expanding infrastructure footprint.

Imagion Biosystems reported a $1.66 million loss for the half-year ending June 2025 while progressing its MagSense® HER2 Imaging Agent towards a Phase 2 FDA trial and securing $3.5 million in new funding.

Cyclopharm Limited reported a 26% revenue increase for the half year ended June 2025, driven by rapid US market expansion and strong growth in its Third-Party distribution business. Despite a wider net loss, the company secured a key patent extension and reaffirmed its target to install 250-300 Technegas® systems in the US by late 2026.

Enlitic, Inc. reported a sharp revenue increase driven by migration services and subscription growth, while sustaining a net loss of US$6.86 million in H1 2025. The company secured a binding MOU with GE Healthcare and completed a A$10 million capital raise.

BPH Energy Limited reported a 49% increase in net profit for FY2025, driven by gains in its energy and biotech investments, while facing a pivotal Federal Court hearing over the renewal of the PEP-11 offshore gas exploration permit.

Nova Eye Medical has delivered solid FY25 results, meeting sales guidance outside China and achieving six consecutive halves of growth in the US market. The company also improved gross margins and reduced cash burn, setting an optimistic tone for FY26 with breakeven EBITDA guidance.

Savannah Goldfields Limited has announced a $15 million equity raising through a placement and conditional placement, offering free attaching options subject to shareholder approval. The capital raise aims to strengthen the company’s financial position and support its operational restart plans.

Nova Eye Medical Limited reported a 25% increase in revenue to AUD 29.3 million for FY2025, driven by strong sales in its glaucoma surgical devices segment, yet posted a net loss after tax of AUD 9.1 million. The company raised AUD 6.2 million through a share placement to support growth initiatives.

Mesoblast Limited is set to release its full-year financial results and operational highlights for 2025, spotlighting its FDA-approved cell therapy and expanding global partnerships.